Your session is about to expire
← Back to Search
iTind vs UroLift for Enlarged Prostate (MT-08 Trial)
MT-08 Trial Summary
This trialwill compare the safety of a new prostate treatment called iTind to the already approved UroLift.
MT-08 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowMT-08 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.MT-08 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I cannot stop taking my alpha blockers or 5ARIs for the required time.I am a man aged 50 or older.My prostate's median lobe is enlarged, confirmed by imaging.I have not had blood in my urine or bladder stones in the last 3 months.You are allergic or have a strong suspicion of being allergic to nickel, titanium, or polyester/polypropylene.I have been diagnosed with a condition affecting my bladder or urethra.My prostate is larger than 75 cc.I have symptoms from an enlarged prostate that needs treatment.I have bladder control issues due to a neurological condition like Parkinson's or diabetes.I use a catheter or cannot urinate on my own.I have had prostatitis in the last 2 years.I have a significant pouch in my bladder.I currently have a urinary tract infection.My prostate cancer has been thoroughly checked by MRI and/or biopsy.I was diagnosed with bladder cancer in the last 2 years.I am willing and able to attend all study visits and complete questionnaires.I have had surgeries or treatments in my pelvic area that might interfere with certain prostate or urinary treatments.My prostate size is 75 cc or less, confirmed by imaging within the last 6 months.My urine flow rate is between 5 and 12 mL/sec.I have not taken any blood thinners except for low-dose aspirin in the last week.I have symptoms from an enlarged prostate that needs treatment.
- Group 1: iTind arm
- Group 2: UroLift
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does the eligibility criteria of this investigation include persons aged 45 and above?
"The entry requirements for this clinical trial stipulate that the minimum age of enrollees must be at least 50, while the upper limit is set to 80 years old."
Does my present condition meet the criteria to join this medical investigation?
"Participants with benign prostatic hyperplasia (bph) between the ages of 50 and 80 are welcome to apply for this study. The recruitment goal is 250 patients in total."
Is enrollment currently available for this trial?
"Affirmative. Clinicaltrials.gov data affirms that this clinical trial, which was initially publicized on September 26th 2022, is currently recruiting participants. A total of 250 individuals need to be enrolled from 11 different medical centres."
How many health care facilities are facilitating this investigation?
"The University of Toledo in Toledo, Ohio; the University of Kansas Medical Research Institute, Inc. in Kansas City, Kansas; Golden State Urology in Sacramento California are among 11 other sites offering this medical trial."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger